JPMorgan Chase & Co. Increases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

JPMorgan Chase & Co. increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 85.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 68,148 shares of the company’s stock after buying an additional 31,352 shares during the quarter. JPMorgan Chase & Co. owned about 0.10% of Nurix Therapeutics worth $1,531,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in Nurix Therapeutics by 80.7% during the second quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock worth $6,762,000 after buying an additional 144,700 shares in the last quarter. Barclays PLC grew its stake in Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares in the last quarter. FMR LLC grew its stake in Nurix Therapeutics by 675.9% during the 3rd quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after purchasing an additional 511,256 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Nurix Therapeutics during the 3rd quarter worth about $530,000. Finally, Franklin Resources Inc. lifted its holdings in Nurix Therapeutics by 52.4% during the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock worth $2,766,000 after buying an additional 42,315 shares during the last quarter.

Nurix Therapeutics Trading Up 1.4 %

Shares of NRIX opened at $19.96 on Friday. The firm has a market capitalization of $1.41 billion, a P/E ratio of -6.86 and a beta of 2.14. The stock’s fifty day simple moving average is $20.50 and its 200 day simple moving average is $22.46. Nurix Therapeutics, Inc. has a twelve month low of $7.65 and a twelve month high of $29.56.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,437 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $83,519.10. Following the transaction, the insider now directly owns 50,670 shares of the company’s stock, valued at $1,231,281. This trade represents a 6.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $24.28, for a total value of $86,096.88. Following the completion of the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at $818,818.72. This trade represents a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,351 shares of company stock valued at $227,158 over the last three months. 7.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

NRIX has been the subject of several research reports. Jefferies Financial Group began coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets began coverage on Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. UBS Group initiated coverage on Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. Finally, HC Wainwright increased their price target on Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $30.35.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.